

## Contents

**List of Contributors** XIII

**Preface** XVII

**A Personal Foreword** XXI

### **Part One General Aspects and Methodologies** 1

#### **1 New Frontiers in Epigenetic Modifications** 3

*Adam L. Garske and John M. Denu*

- 1.1 Introduction 3
- 1.2 DNA Methylation 3
- 1.3 Histone Modifications and the Histone Code Hypothesis 5
- 1.4 Origins of Specificity in Histone Binding Proteins/Modifying Enzymes 7
- 1.5 Histone Modification Cross-talk 11
- 1.6 Inhibitors of DNMTs and HDACs 13
- 1.7 Conclusions 17
- References 17

#### **2 Structural Biology of Epigenetic Targets** 23

*Christophe Romier, Jean-Marie Wurtz, Jean-Paul Renaud, and Jean Cavarelli*

- 2.1 Introduction 23
- 2.2 Histone Acetyltransferases 24
  - 2.2.1 Structures from the GNAT Family 24
  - 2.2.2 Structures of HATs from the MYST Family 26
  - 2.2.3 Structure of the p300 and Rtt109 HATs 26
  - 2.2.4 Binding of Histone Substrates by HATs of the GNAT Family 27
  - 2.2.5 Catalytic Mechanism of HATs 29
- 2.3 Histone Deacetylases 29

2.3.1	Structure of HDACs	30
2.3.2	Binding of Acetylated Lysine by HDACs	32
2.3.3	Catalytic Mechanism of HDACs	32
2.3.4	Structural Basis of Inhibition of HDACs	33
2.4	Sirtuins	34
2.4.1	Structure of Sirtuins	34
2.4.2	Catalytic Mechanism of Sirtuins	35
2.5	Histone Methylation Enzymes	35
2.5.1	Histone Lysine Methyltransferases	36
2.5.1.1	SET Domain of HKMTs	36
2.5.1.2	Dot1 HKMTs	38
2.5.2	Histone Arginine Methyltransferases	39
2.6	Histone Demethylases	39
2.6.1	Lysine Histone Demethylases	41
2.6.1.1	LSD1 (KDM1)	41
2.6.1.2	The JmjC Family: Jumonji-C Domain Containing Proteins	42
2.6.1.3	Lysine Demethylase JHDM1 (KDM2)	43
2.6.1.4	Lysine Demethylase JHDM3/JMJD2 (KDM4)	43
2.6.2	Arginine Demethylases	44
2.6.2.1	Histone Demethylation	44
2.6.2.2	Histone Arginine Demethylase	45
2.7	DNA Methyltransferases	46
2.8	Concluding Remarks: the Challenge of Structural Studies of Epigenetic Targets	47
	References	49

### **3 Computer- and Structure-Based Lead Identification for Epigenetic Targets** 57

*Ralf Heinke, Urszula Uciechowska, and Wolfgang Sippl*

3.1	Introduction	57
3.2	Computer-Based Methods in Drug Discovery	58
3.2.1	Pharmacophore-Based Methods	58
3.2.2	3D Quantitative Structure–Activity Relationship	59
3.2.3	Ligand Docking	59
3.2.4	Virtual Screening	60
3.2.5	Binding Free Energy Calculations	60
3.3	DNA Methyltransferases	61
3.4	Histone Deacetylases	62
3.4.1	Classic HDACs	62
3.4.1.1	Docking Studies Using X-Ray Structures and Homology Models	63
3.4.1.2	3D-QSAR Studies	64
3.4.1.3	Virtual Screening Studies	64
3.4.2	Sirtuins	66

3.5	Histone Acetyltransferases	73
3.6	Histone Methyltransferases	74
3.7	Histone Demethylases	78
3.8	Summary	79
	References	79
<b>4</b>	<b>Histone Modification Analysis Using Mass Spectrometry</b>	<b>87</b>
	<i>Ana Villar-Garea and Axel Imhof</i>	
4.1	Introduction	87
4.2	Histone Molecules	88
4.3	Capillary Electrophoresis	88
4.4	Reversed Phase Chromatography	89
4.5	Mass Spectrometry	89
	References	94
<b>5</b>	<b><i>In Vitro</i> Assays for Histone-Modifying Enzymes</b>	<b>99</b>
	<i>Alexander-Thomas Hauser and Manfred Jung</i>	
5.1	Introduction	99
5.2	Screening Hierarchy	99
5.3	General Principles of Screening for Histone-Modifying Enzymes	100
5.4	Histone Deacetylases	101
5.4.1	Radioactive Assays	101
5.4.2	Fluorescent Assays	104
5.5	Histone Acetyltransferases	107
5.5.1	Radioactive Assays	107
5.5.2	Assays Based on CoA-SH Detection	107
5.5.3	Antibody-Based Assays	108
5.6	Histone Methyltransferases	110
5.6.1	Arginine Methyltransferases	110
5.6.2	Lysine Methyltransferases	110
5.7	Histone Demethylases	111
5.7.1	Lysine Demethylases	111
5.7.2	Arginine Demethylases	113
5.8	Conclusion	113
	References	113
<b>6</b>	<b>Epigenetic Targets in Drug Discovery: Cell-Based Assays for HDAC Inhibitor Hit Validation</b>	<b>119</b>
	<i>Mira Jung, Kwon-Jeong Yong, Alfredo Velena, and Sung Lee</i>	
6.1	Introduction	119
6.2	<i>In Vitro</i> Assays for HDAC Inhibitors	120
6.2.1	<i>In Vitro</i> Enzymatic Assay and Substrate Specificity	120
6.2.2	<i>In Vitro</i> High-Throughput Assays	121
6.2.3	<i>In Vitro</i> Isoform-Specificity Assays	121

6.3	Cell-Based Assays	122
6.3.1	HDAC Activity Assays in Cultured Cells	123
6.3.2	Detection of Acetylated Histones and Nonhistone Proteins	123
6.4	Biological Function-Based Assays	125
6.4.1	Cell Proliferation Assays	125
6.4.2	Reporter Systems	125
6.4.3	High-Throughput Gene Expression Analysis	126
6.4.4	Flow Cytometry Analysis	127
6.5	HDAC Isoform Functional Assays	128
6.5.1	Depletion of Target Genes in Cells	128
6.5.2	Knockout Animal Models	129
6.6	Anticancer Activity	129
6.6.1	Antiangiogenic Assays	129
6.6.2	Invasion Assay	130
6.6.3	Tumor Xenograft Models	130
6.7	Perspective	131
	References	132
<b>7</b>	<b>Chromatin Immunoprecipitation ChIP: Wet Lab Meets <i>In Silico</i></b>	<b>139</b>
	<i>Martin Seifert and Robert Schneider</i>	
7.1	Background and Overview	139
7.1.1	Chromatin and DNA Organization	139
7.1.2	Chromatin Immunoprecipitation as a Powerful Method to Study Chromatin	140
7.2	The Basic Principle of ChIP	141
7.2.1	N-ChIP	142
7.2.2	X-ChIP	142
7.2.3	Choice of DNA Fragmentation Method	143
7.2.4	Choice of Antibodies	143
7.3	Different Variations of ChIP	144
7.3.1	ChIP-On-Chip	144
7.3.2	ChIPDSL	144
7.3.3	ChIP-Sequencing	145
7.3.4	Re-ChIP	145
7.3.5	ChIP-Chop	145
7.3.6	Methyl-DNA Immunoprecipitation (MeDIP)	146
7.4	Analysis of ChIP Data	146
7.4.1	Detection and Definition of Enriched Regions in ChIP-on-Chip Experiments	146
7.4.2	Detection and Definition of Enriched Regions in ChIP-Seq Experiments	146
7.4.3	Annotation of Enriched Regions	148
7.4.4	Analysis of Enriched Regions	148
7.5	Data Analysis Examples	149

7.6	The Future of ChIP	156
	References	157

## Part Two Epigenetic Target Classes and Inhibitor Development 161

<b>8</b>	<b>DNA Methyltransferase Inhibitors</b>	<b>163</b>
	<i>Wolfgang Sippl and Manfred Jung</i>	
8.1	Introduction	163
8.2	DNA Methylation	163
8.3	DNA Methyltransferases	165
8.4	Biochemical Mechanism of DNA Methylation	168
8.5	Physiological Role of DNA Methylation	168
8.6	DNA Methylation and Disease	169
8.7	DNMT Inhibitors	170
8.7.1	Covalent DNMT Inhibitors	170
8.7.2	Noncovalent DNMT Inhibitors	173
8.8	Therapeutic Applications of DNMT Inhibitors	175
8.9	Conclusion	176
	References	176
<b>9</b>	<b>Histone Deacetylase Inhibitors</b>	<b>185</b>
	<i>Philip Jones</i>	
9.1	Introduction	185
9.2	Mechanism and X-Ray Crystal Structure	186
9.3	Histone Deacetylase Inhibitors	188
9.3.1	Short-Chain Fatty Acids	188
9.3.2	Hydroxamic Acids	190
9.3.2.1	Aliphatic Hydroxamic Acids	192
9.3.2.2	Cinnamic Hydroxamic Acids	194
9.3.2.3	Phenyl Hydroxamic Acids	197
9.3.2.4	Heterocycle Hydroxamic Acids	198
9.3.3	Aminoanilines	200
9.3.3.1	HDAC1 and 2 Selective Aminoanilines	204
9.3.4	Electrophilic Ketones	206
9.3.5	Natural Products	208
9.3.6	Hybrid Cyclic Tetrapeptides	212
9.3.7	Aliphatic Ketones	213
9.3.8	Thiols and Related HDAC Inhibitors	213
9.4	Conclusions	216
	References	216
<b>10</b>	<b>NAD-Dependent Deacetylases as Therapeutic Targets</b>	<b>225</b>
	<i>Hongzhe Li, Julian Simon, and Antonio Bedalov</i>	
10.1	Historical Perspective and Functions of Sir2 in Yeast	225

10.2	Sirtuin Enzymatic Activity and its Modulation by Endogenous Molecules	226
10.3	Small Molecule Inhibitors of Sirtuins	228
10.4	Small Molecule Activators of Sirtuins	230
10.5	SIRT1 as a Therapeutic Target in Metabolic Syndrome and Type 2 Diabetes	231
10.5.1	Sirtuins and Cancer	232
10.6	Neurological Diseases	234
10.7	Conclusion	235
	References	236
<b>11</b>	<b>Inhibitors of Histone Acetyltransferases: Discovery and Biomedical Perspectives</b>	<b>243</b>
	<i>Margarete von Wantoch Rekowski and Athanassios Giannis</i>	
11.1	Introduction	243
11.2	HAT Inhibitors	245
11.3	Summary	248
	References	249
<b>12</b>	<b>Histone Methyltransferases as Novel Drug Targets</b>	<b>251</b>
	<i>Manfred Jung</i>	
12.1	Introduction	251
12.2	Protein Methylation	251
12.2.1	Arginine Methylation	252
12.2.2	Lysine Methylation	253
12.3	Histone Demethylation	254
12.4	Histone Methyltransferases	254
12.4.1	Arginine Methyltransferases	254
12.4.2	Lysine Methyltransferases	256
12.5	Histone Methyltransferase Inhibitors	257
12.5.1	Arginine Methyltransferase Inhibitors	257
12.5.2	Lysine Methyltransferase Inhibitors	260
12.6	Concluding Remarks	262
	References	262
<b>13</b>	<b>Histone Demethylases</b>	<b>269</b>
	<i>Rasmus P. Clausen, Marianne T. Pedersen, and Kristian Helin</i>	
13.1	Introduction	269
13.2	Chromatin	269
13.3	Histone Methylation and Demethylation	270
13.4	Histone Demethylases	271
13.5	LSD1/KDM1	273
13.5.1	Inhibitors of LSD1	274
13.6	JmjC Domain-Containing Demethylases	276
13.6.1	The FBXL/KDM2 Cluster	277

13.6.2	The JMJD1/KDM3 Cluster	279
13.6.3	The JMJD2/KDM4 Cluster	280
13.6.4	The JARID1/KDM5 Cluster	280
13.6.5	The UTX/JMJD3 (KDM6) Cluster	282
13.6.6	Inhibitors of JmjC Domain-Containing Demethylases	282
13.7	Summary	283
	References	284
	<b>Index</b>	291

